GO
Loading...

Enter multiple symbols separated by commas

Stocks GlaxoSmithKline PLC

More

  • NEW YORK— Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:. Yelp Inc., down $8.45 to $25.06. Twitter Inc., down $5.30 to $31.24.

  • *HIV sales help offset margin slide post Novartis deal. LONDON, July 29- GlaxoSmithKline moved to reclaim its prowess as a research powerhouse on Wednesday by flagging up dozens of new drugs and vaccines in development, as demand for new HIV medicines helped it beat quarterly profit forecasts. The drugmaker recently sold its marketed cancer drugs to Novartis...

  • Drugmaker GSK sees earnings growth returning in 2016 Wednesday, 29 Jul 2015 | 8:16 AM ET

    LONDON— Britain- based drugmaker GlaxoSmithKline has reported a drop in earnings in the first full quarter since its deal to swap some assets with Swiss rival Novartis. CEO Andrew Witty described the performance as encouraging, with plans on track to integrate and restructuring operations it took over from Novartis in April. In the deal, GSK agreed to sell its...

  • Early movers: HLT, ANTM, ETN, TWTR, GSK & more Wednesday, 29 Jul 2015 | 7:54 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • *Margins slide in first full quarter after Novartis deal. LONDON, July 29- A further slide in sales of lung drug Advair and lower profit margins following a business overhaul hit GlaxoSmithKline in the second quarter, although core earnings per share fell by a less than expected 9 percent. The drugmaker recently sold its marketed cancer drugs to Novartis and...

  • Fed meeting may bring more volatility than expected Wednesday, 29 Jul 2015 | 6:44 AM ET
    Traders work on the floor of the New York Stock Exchange.

    No matter how much it tries to avoid it, the Fed could get markets spinning on a fresh round of rate hike speculation Wednesday.

  • Fed statement may bring more volatility than expected Wednesday, 29 Jul 2015 | 6:02 AM ET
    Traders work on the floor of the New York Stock Exchange.

    No matter how much it tries to avoid it, the Fed could get markets spinning on a fresh round of rate hike speculation Wednesday.

  • Top trades to go: Earnings edition Tuesday, 28 Jul 2015 | 1:43 PM ET

    The "Halftime Report" traders give their trades on earnings for the second half.

  • Forget US earnings—Europe may be about to surprise Monday, 27 Jul 2015 | 12:53 PM ET

    After a week dominated by U.S. quarterly results, it's time for Europe's earnings season to get into full swing, and so far the signs are upbeat.

  • Minefield for market with Fed, earnings, commodities Monday, 27 Jul 2015 | 8:08 AM ET
    An oil trader works on the floor of the New York Mercantile Exchange.

    The Fed meets next week, but a commodities meltdown and earnings season are adding to concerns about global growth and may steal some of its thunder.

  • Allergan buys Naurex for $560M as deal talk swirls Sunday, 26 Jul 2015 | 11:20 AM ET
    A clinical technician holds a syringe and a vial of Allergan Botox, produced by Allergan.

    Allergan is considering a breakup of the company into two businesses, a person familiar with the matter told Reuters on Friday.

  • Early movers: CI, AMZN, SAVE, BIIB, MCO, T & more Friday, 24 Jul 2015 | 7:54 AM ET

    Some of the names on the move ahead of the open.

  • *EU regulators back GSK's Mosquirix for babies in Africa. LONDON, July 24- The world's first malaria vaccine got a green light on Friday from European drugs regulators who recommended it as safe and effective to use in babies in Africa at risk of the mosquito-borne disease. Mosquirix, also known as RTS, S and part-funded by the Bill& Melinda Gates Foundation, will now...

  • LONDON— The European Medicines Agency has recommended approving what would be the world's first licensed malaria vaccine, even though it's only about 30 percent effective and its protection fades over time. The recommendation to license the vaccine, known as Mosquirix and made by GlaxoSmithKline, must still be approved by the European Commission.

  • LONDON, July 24- The world's first malaria vaccine got a green light on Friday from European drugs regulators who recommended it should be licensed for use in babies in Africa at risk of the mosquito-borne disease. Recommendations for a drug licence made by the European Medicines Agency are normally endorsed by the European Commission within a couple of...

  • *Vaccine developed by GlaxoSmithKline for babies in Africa. LONDON, July 24- The world's first malaria vaccine got a green light on Friday from European drugs regulators who recommended it should be licensed for use in babies in Africa at risk of the mosquito-borne disease. The shot, called RTS, S or Mosquirix and developed by British drugmaker GlaxoSmithKline...

  • Pfizer has expanded its research on vaccines to eventually safeguard people from cradle to grave, from shots for pregnant women to protect their babies from the moment of birth to vaccines for senior citizens with waning immune systems, company officials said Tuesday during a media briefing. New York- based Pfizer Inc. has long talked of building its...

  • July 21- Novavax Inc said its experimental Ebola vaccine induced a substantial immune response to the deadly infection in an early-stage trial involving 230 healthy adults. Potential partners include the Biomedical Advanced Research and Development Authority, a division of U.S. Department of Health and Human Services, which Novavax is already working...

  • Novavax rises on promising Ebola vaccine trial Tuesday, 21 Jul 2015 | 9:39 AM ET
    In this handout from the Center for Disease Control, a colorized transmission electron micrograph (TEM) of a Ebola virus virion is seen.

    Novavax shares rose at Tuesday's market open after the bio-pharmaceutical firm said its Ebola vaccine showed promising early results.

  • July 21- Novavax Inc said its experimental Ebola vaccine induced a substantial immune response to the deadly infection in an early-stage trial involving 230 healthy adults. Vaccines being developed by Bavarian Nordic, GlaxoSmithKline and Johnson& Johnson have entered mid-stage studies. Gaithersburg, Maryland- based Novavax's shares have risen more than...